MVA-member company, Ascelia Pharma, is considering listing on the stock exchange

    According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies. A listing  on the stock exchange is one of the options being considered, Magnus Corfitzen, explains Medwatch in the recently published article. Read full interview here